Proteome Sciences plc is a public limited company and a leader in applied proteomics and peptidomics, specializing in protein biomarker research and development. The company employs high-sensitivity proprietary technologies, including multiplexed TMT-based mass spectrometry, to detect, characterize, and quantify proteins and peptides in complex biological samples such as solids and fluids. This expertise supports precision medicine by delivering services, biomarkers, and reagents that address major human diseases with significant unmet needs, enabling more effective prognostic, therapeutic, and clinical trial applications. Operating as a contract research organization (CRO), Proteome Sciences plc provides outsourced services under ISO-9001:2015 or GCLP standards, offering complementary insights for partners developing targeted therapeutics and cost-efficient healthcare solutions. Headquartered in Cobham, Surrey, United Kingdom, and founded in 1993, the firm plays a key role in the diagnostics and research sector of healthcare, with a mission to transform disease management at the individual level through innovative proteomic content.